SNC116 cell therapy for hard-to-treat lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy called SNC116 for people with lupus that has not improved with standard treatments. The treatment aims to reset the immune system to reduce disease activity and may help those with severe lupus or kidney inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus and your disease is still active despite at least 6 months of standard treatments.
- If you have lupus-related kidney disease, you must have had a kidney biopsy showing active inflammation and significant protein in your urine.
- Your blood counts must be within certain limits (for example, enough white blood cells and platelets).
- You must agree to use effective birth control during the study and for 2 years after treatment, and not donate blood or organs during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This trial tests a new cell therapy (RJMty19) for people with lupus that hasn't improved with standard treatments. It aims to reduce disease activity and may help those with active organ involvement.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.